Valion Bio, Inc.
VBIO
$1.10
-$0.01-0.90%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -61.28% | -49.63% | -58.49% | -54.50% | -33.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -61.28% | -49.63% | -58.49% | -54.50% | -33.67% |
| Cost of Revenue | -4.46% | -51.76% | -83.31% | -73.27% | -59.62% |
| Gross Profit | -117.01% | -116.67% | -52.26% | -63.64% | -16.03% |
| SG&A Expenses | 50.71% | -29.47% | -42.63% | -54.18% | -54.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 76.45% | -19.73% | -38.31% | -51.54% | -52.49% |
| Operating Income | -76.45% | 3.13% | 23.43% | 40.85% | 45.71% |
| Income Before Tax | -78.81% | 1.56% | 23.61% | 40.98% | 45.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -78.81% | 1.56% | 23.61% | 40.98% | 45.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.99% | -16.90% | 6.06% | 25.40% | 31.40% |
| EBIT | -76.45% | 3.13% | 23.43% | 40.85% | 45.71% |
| EBITDA | -76.46% | 3.09% | 23.43% | 40.84% | 45.70% |
| EPS Basic | 71.86% | 84.39% | 86.27% | 93.01% | 92.06% |
| Normalized Basic EPS | 69.98% | 92.51% | 91.88% | 95.18% | 93.23% |
| EPS Diluted | 71.86% | 84.39% | 86.27% | 93.01% | 92.06% |
| Normalized Diluted EPS | 69.98% | 92.51% | 91.88% | 95.18% | 93.23% |
| Average Basic Shares Outstanding | 306.04% | 299.16% | 344.62% | 469.64% | 423.55% |
| Average Diluted Shares Outstanding | 306.04% | 299.16% | 344.62% | 469.64% | 423.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |